150 related articles for article (PubMed ID: 35737164)
21. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
23. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
WANG J; GAO J; HE J
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
27. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.
Ono A; Naito T; Ito I; Watanabe R; Shukuya T; Kenmotsu H; Tsuya A; Nakamura Y; Murakami H; Kaira K; Takahashi T; Kameya T; Nakajima T; Endo M; Yamamoto N
Lung Cancer; 2012 Jun; 76(3):439-44. PubMed ID: 22300752
[TBL] [Abstract][Full Text] [Related]
28. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS.
Torsetnes SB; Levernæs MS; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Chem; 2014 Jul; 86(14):6983-92. PubMed ID: 24945626
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis.
Yang HJ; Gu Y; Chen C; Xu C; Bao YX
Clin Chem Lab Med; 2011 Jun; 49(6):1039-46. PubMed ID: 21649553
[TBL] [Abstract][Full Text] [Related]
30. IL-6 and VEGF in small cell lung cancer patients.
Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK
Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377
[TBL] [Abstract][Full Text] [Related]
31. Selection of DNA aptamers with affinity for pro-gastrin-releasing peptide (proGRP), a tumor marker for small cell lung cancer.
Mie M; Kai T; Le T; Cass AE; Kobatake E
Appl Biochem Biotechnol; 2013 Jan; 169(1):250-5. PubMed ID: 23179274
[TBL] [Abstract][Full Text] [Related]
32. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
33. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
34. Algorithm using Neuron-Specific Enolase and Pro-Gastrin-Releasing Peptide to Increase the Diagnostic Accuracy for Small Cell Lung Cancer.
Lee H; Park SD; Kim T; Kim J; Jang TW; Choi H; Hwang H
Ann Lab Med; 2021 May; 41(3):339-341. PubMed ID: 33303722
[No Abstract] [Full Text] [Related]
35. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
Giovanella L; Ceriani L; Bandera M; Garancini S
Int J Biol Markers; 2001; 16(1):50-5. PubMed ID: 11288956
[TBL] [Abstract][Full Text] [Related]
36. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
[TBL] [Abstract][Full Text] [Related]
37. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
39. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
